Physician profile
David Siu
NPI 1255303939
$5,182.11
in general payments reported to CMS, 2019-2025
36 companies · $730 in 2025
The $730 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $455 · 2021: $576 · 2022: $700 · 2023: $813 · 2024: $1,326 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Consulting Fee: $375 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.55 |
| Consulting Fee | $375.00 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $687.91 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $646.76 | 2019-2025 | |
| Amgen INC. | $514.89 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $356.36 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $305.38 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $245.95 | 2019-2025 | Velphoro, Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $224.26 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $201.09 | 2021-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $179.77 | 2019-2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $177.67 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $163.55 | 2020-2025 | Vafseo |
| Glaxosmithkline, LLC. | $160.69 | 2021-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $157.46 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $126.19 | 2021-2025 | Rayaldee |
| Kyowa Kirin, INC. | $113.22 | 2023-2025 | Crysvita |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $109.55 | 2024-2025 | |
| Ardelyx, INC. | $106.11 | 2023-2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $101.43 | 2021-2024 | Crysvita, Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $95.82 | 2020-2024 | Gattex |
| Baxter Healthcare | $94.15 | 2019-2023 | Renal - Acute |
| Aurinia Pharma U.S., INC. | $66.61 | 2021-2022 | |
| Horizon Therapeutics Plc | $54.12 | 2021-2023 | Krystexxa |
| Alnylam Pharmaceuticals INC. | $35.07 | 2021 | |
| Lilly USA, LLC | $29.21 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $26.33 | 2025 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $24.86 | 2019 | |
| Scpharmaceuticals INC. | $24.16 | 2025 | |
| Biomerieux INC | $21.00 | 2023 | |
| Amag Pharmaceuticals, INC. | $20.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2023 | Jardiance |
| Avenu Medical INC. | $19.62 | 2020 | |
| Novo Nordisk INC | $19.44 | 2025 | Ozempic |
| Daiichi Sankyo INC. | $19.12 | 2019 | |
| Medtronic, INC. | $18.74 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.15 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Siu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.